Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back ...

No sooner did Eli Lilly (NYSE: LLY)’s oral diabetes candidate orforglipron make history Thursday as the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist to ace a Phase ...

Eli Lilly stock has been a big-time winner over the last couple of years, but looming tariffs are worrying some investors. The pharmaceutical sector could be the next industry to face sweeping ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best low volatility stocks to buy now. The US stock market experienced a turbulent first ...

A new daily weight-loss pill could be just as effective as the popular injectables that help patients lower their blood sugar and lose unwanted weight. "I think we're really at the beginning of a ...

"Be mindful about what you're sharing, because once it's online, it's online forever," says Lilly Sabri. The fitness influencer, who has six million followers on YouTube, has urged fans to heed ...

Eli Lilly & Co. (LLY) announced Friday that it plans to manufacture its experimental weight-loss pill in the U.S. as President Trump emphasizes reshoring manufacturing to the U.S. “We’re going ...

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%. Last year was a transformative year for the Indianapolis-based pharmaceutical giant ...

Eli Lilly’s new GLP-1 weight loss drug, in pill form, would be more affordable than Ozempic Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other other firms that ended the week strong. The stock market ended the shortened trading ...